FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281570794> ?p ?o ?g. }

• W4281570794 endingPage "102133" @default.
• W4281570794 startingPage "102133" @default.
• W4281570794 abstract "Janus Kinases (JAKs) mediate activity of many asthma-relevant cytokines. GDC-0214, an inhaled small molecule JAK1 inhibitor, has previously been shown to reduce fractional exhaled nitric oxide (FeNO) in patients with mild asthma, but required an excessive number of inhalations.To assess whether GDC-4379, a new inhaled JAK inhibitor, reduces FeNO and peripheral biomarkers of inflammation.This study assessed the activity of GDC-4379 in a double-blind, randomized, placebo-controlled, Phase 1 study in patients with mild asthma. Participants included adults (18-65y) with a diagnosis of asthma for ≥6 months, forced expiratory volume in 1 s (FEV1)> 70% predicted, FeNO >40 ppb, using as-needed short-acting beta-agonist medication only. Four sequential, 14-day, ascending-dose cohorts (10 mg QD, 30 mg QD, 40 mg BID, and 80 mg QD) of 12 participants each were randomized 2:1 to GDC-4379 or placebo. The primary activity outcome was percent change from baseline (CFB) in FeNO to Day 14 compared to the pooled placebo group. Safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers, including blood eosinophils, serum CCL17, and serum CCL18, were also assessed.Of 48 enrolled participants, the mean age was 25 years and 54% were female. Median (range) FeNO at baseline was 79 (41-222) ppb. GDC-4379 treatment led to dose-dependent reductions in FeNO. Compared to placebo, mean (95% CI) percent CFB in FeNO to Day 14 was: -6 (-43, 32) at 10 mg QD, -26 (-53, 2) at 30 mg QD, -55 (-78, -32) at 40 mg BID and -52 (-72, -32) at 80 mg QD. Dose-dependent reductions in blood eosinophils and serum CCL17 were also observed. Higher plasma drug concentrations corresponded with greater FeNO reductions. No serious AEs occurred. The majority of AEs were mild to moderate. The most common AEs were headache and oropharyngeal pain. Minor changes in neutrophils were noted at 80 mg QD, but were not considered clinically meaningful.In patients with mild asthma, 14-day treatment with GDC-4379 reduced FeNO levels and peripheral biomarkers of inflammation. Treatment was well tolerated without any major safety concerns.ACTRN12619000227190." @default.
• W4281570794 created "2022-05-27" @default.
• W4281570794 creator A5004069385 @default.
• W4281570794 creator A5015032333 @default.
• W4281570794 creator A5018805442 @default.
• W4281570794 creator A5021064205 @default.
• W4281570794 creator A5027257135 @default.
• W4281570794 creator A5031306306 @default.
• W4281570794 creator A5039755983 @default.
• W4281570794 creator A5048765625 @default.
• W4281570794 creator A5053952710 @default.
• W4281570794 creator A5056881138 @default.
• W4281570794 creator A5057670379 @default.
• W4281570794 creator A5060103929 @default.
• W4281570794 creator A5060974095 @default.
• W4281570794 creator A5074384647 @default.
• W4281570794 creator A5075454320 @default.
• W4281570794 creator A5080798319 @default.
• W4281570794 creator A5080961778 @default.
• W4281570794 creator A5082723983 @default.
• W4281570794 creator A5083793220 @default.
• W4281570794 creator A5085000447 @default.
• W4281570794 creator A5091241406 @default.
• W4281570794 creator A5091297501 @default.
• W4281570794 date "2022-08-01" @default.
• W4281570794 modified "2023-10-16" @default.
• W4281570794 title "Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation" @default.
• W4281570794 cites W2013105339 @default.
• W4281570794 cites W2013695939 @default.
• W4281570794 cites W2091380669 @default.
• W4281570794 cites W2123078357 @default.
• W4281570794 cites W2127482775 @default.
• W4281570794 cites W2138355864 @default.
• W4281570794 cites W2141343329 @default.
• W4281570794 cites W2151520766 @default.
• W4281570794 cites W2157748566 @default.
• W4281570794 cites W2167829087 @default.
• W4281570794 cites W2413573154 @default.
• W4281570794 cites W2513258422 @default.
• W4281570794 cites W2515900781 @default.
• W4281570794 cites W2754586014 @default.
• W4281570794 cites W2803941918 @default.
• W4281570794 cites W2888157059 @default.
• W4281570794 cites W2890925318 @default.
• W4281570794 cites W2971454662 @default.
• W4281570794 cites W3137707134 @default.
• W4281570794 cites W3162024685 @default.
• W4281570794 cites W4226373090 @default.
• W4281570794 cites W4251519441 @default.
• W4281570794 doi "https://doi.org/10.1016/j.pupt.2022.102133" @default.
• W4281570794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35644305" @default.
• W4281570794 hasPublicationYear "2022" @default.
• W4281570794 type Work @default.
• W4281570794 citedByCount "2" @default.
• W4281570794 countsByYear W42815707942023 @default.
• W4281570794 crossrefType "journal-article" @default.
• W4281570794 hasAuthorship W4281570794A5004069385 @default.
• W4281570794 hasAuthorship W4281570794A5015032333 @default.
• W4281570794 hasAuthorship W4281570794A5018805442 @default.
• W4281570794 hasAuthorship W4281570794A5021064205 @default.
• W4281570794 hasAuthorship W4281570794A5027257135 @default.
• W4281570794 hasAuthorship W4281570794A5031306306 @default.
• W4281570794 hasAuthorship W4281570794A5039755983 @default.
• W4281570794 hasAuthorship W4281570794A5048765625 @default.
• W4281570794 hasAuthorship W4281570794A5053952710 @default.
• W4281570794 hasAuthorship W4281570794A5056881138 @default.
• W4281570794 hasAuthorship W4281570794A5057670379 @default.
• W4281570794 hasAuthorship W4281570794A5060103929 @default.
• W4281570794 hasAuthorship W4281570794A5060974095 @default.
• W4281570794 hasAuthorship W4281570794A5074384647 @default.
• W4281570794 hasAuthorship W4281570794A5075454320 @default.
• W4281570794 hasAuthorship W4281570794A5080798319 @default.
• W4281570794 hasAuthorship W4281570794A5080961778 @default.
• W4281570794 hasAuthorship W4281570794A5082723983 @default.
• W4281570794 hasAuthorship W4281570794A5083793220 @default.
• W4281570794 hasAuthorship W4281570794A5085000447 @default.
• W4281570794 hasAuthorship W4281570794A5091241406 @default.
• W4281570794 hasAuthorship W4281570794A5091297501 @default.
• W4281570794 hasConcept C111113717 @default.
• W4281570794 hasConcept C112705442 @default.
• W4281570794 hasConcept C126322002 @default.
• W4281570794 hasConcept C142724271 @default.
• W4281570794 hasConcept C197934379 @default.
• W4281570794 hasConcept C204787440 @default.
• W4281570794 hasConcept C27081682 @default.
• W4281570794 hasConcept C2776042228 @default.
• W4281570794 hasConcept C2778375690 @default.
• W4281570794 hasConcept C2780333948 @default.
• W4281570794 hasConcept C2781142857 @default.
• W4281570794 hasConcept C42219234 @default.
• W4281570794 hasConcept C71924100 @default.
• W4281570794 hasConcept C90924648 @default.
• W4281570794 hasConcept C98274493 @default.
• W4281570794 hasConceptScore W4281570794C111113717 @default.
• W4281570794 hasConceptScore W4281570794C112705442 @default.
• W4281570794 hasConceptScore W4281570794C126322002 @default.
• W4281570794 hasConceptScore W4281570794C142724271 @default.
• W4281570794 hasConceptScore W4281570794C197934379 @default.

• next